High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma.
By E. Kimura, M. Nikiforova, Zhaowen Zhu, J. Knauf, Y. Nikiforov, J. Fagin. Cancer Research, 2003
1,567 citations recorded by the source corpus.
View Paper: https://www.semanticscholar.org/paper/8259057fd4d7fb899894ff37c3fa9c2d1cca8798
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- Katherine A. Hoadley
- A. G. Robertson
- S. Baylin
- Peter W. Laird
- Giovanni Ciriello
- Ronglai Shen
- Y. Nikiforov
- Levi A. Garraway
Citations in the corpus
- BRAF mutation in thyroid cancer. (2005, background): “Mutual exclusivity between these two mutations was also seen in thyroid cancer (Fukushima et al. 2003, Kimura et al. 2003, Soares et al. 2003, Frattini et al. 2004).”
- Common SNP in pre-miR-146a decreases mature miR expression and predisposes to papillary thyroid carcinoma (2008, background): “To exclude mislabeling of tumor and normal samples within each pair, we checked tumor samples for the BRAFV600E mutation, which is a frequent somatic change in PTC tumors (5, 6).”
- MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. (2008, background): “The oncogenic mutations in PCs, RET/PTC, BRAF, and RAS are all capable of activation of the MAPK pathway and rarely overlap in the same tumor, suggesting that activation of a single effector of this pathway is sufficient for transformation (31).”
- Integrated Genomic Characterization of Papillary Thyroid Carcinoma (2014, background): “…effectors in the mitogen-activated protein kinase (MAPK) signaling pathway, including point mutations of BRAF and the RAS genes (Cohen et al., 2003; Kimura et al., 2003; Lemoine et al., 1988; Suárez et al., 1988), as well as fusions involving the RET (Grieco et al., 1990) and NTRK1 tyrosine…”
- BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis (2004, background): “BRAF is reportedly mutated in 70% of malignant melanomas (10), in 33% of papillary thyroid carcinomas (11), and in lower frequencies in other cancers (12).”